Role of Hemagarbha Pottali Rasayana Lehana in post COVID-19 lung fibrosis: A case study

The COVID –19 infection mainly presents with respiratory symptoms including a flu like illness with fever cough and asthenia. SARS-CoV-2 can cause severe lung injury. In the high risk population like the elderly or those with multiple co-morbidities. The virus has a higher prevalence of interstitial pneumonia, ARDS and multi organ failure. SARS-CoV-2 uses Angiotensin 2 converting enzyme (ACE2) as a cell receptor in humans, causing interstitial lung damage followed by parenchymal lesions. We report a patient who developed dyspnea, cough, and fever, secondary to pulmonary fibrosis after successful treatment of COVID - 19.

Since 6 months patient was taking treatment for post COVID fibrosis (ILD – UIP pattern) with traction bronchiectasis with severe PAH, Addition of Hemagarbha pottali Rasayana showed promising results as it acts on Pranvaha strotas. It helped to reduce the symptoms of patients like breathlessness, cough, fever and also improved O2 saturation and need of O2 supply.

Observation: There was significant reduction of symptoms and also improved O2 saturation and need of O2 supply. Clinically there was significant reduction in crepts also VAS scale was applied for evaluation of all above symptoms. It was observed that VAS scale score was improved after the treatment.

Conclusion: Hemagarbha Pottali Rasayana is effective in post COVID Lung Fibrosis as an adjuvant treatment along with concomitant medications.